Giancarlo Agnelli

List of Publications by Citations

Source: https://exaly.com/author-pdf/10426055/giancarlo-agnelli-publications-by-citations.pdf

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

327 papers

33,748 citations

73 h-index 181 g-index

346 ext. papers

39,006 ext. citations

8.3 avg, IF

6.88 L-index

#	Paper	IF	Citations
327	Oral rivaroxaban for symptomatic venous thromboembolism. <i>New England Journal of Medicine</i> , 2010 , 363, 2499-510	59.2	2240
326	Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). European Heart Journal, 2008 , 29, 2276-315	9.5	2125
325	2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. <i>European Heart Journal</i> , 2014 , 35, 3033-69, 3069a-3069k	9.5	1974
324	Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. <i>New England Journal of Medicine</i> , 2012 , 366, 1287-97	59.2	1692
323	Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). <i>Chest</i> , 2008 , 133, 454S-545S	5.3	1562
322	Oral apixaban for the treatment of acute venous thromboembolism. <i>New England Journal of Medicine</i> , 2013 , 369, 799-808	59.2	1495
321	Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. <i>Chest</i> , 2004 , 126, 401S-428S	5.3	1000
320	Venous thromboembolism (VTE) in Europe. <i>Thrombosis and Haemostasis</i> , 2007 , 98, 756-764	7	895
319	Apixaban for extended treatment of venous thromboembolism. <i>New England Journal of Medicine</i> , 2013 , 368, 699-708	59.2	882
318	Fibrinolysis for patients with intermediate-risk pulmonary embolism. <i>New England Journal of Medicine</i> , 2014 , 370, 1402-11	59.2	852
317	Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. <i>New England Journal of Medicine</i> , 2002 , 346, 975-80	59.2	799
316	Short-term clinical outcome of patients with acute pulmonary embolism, normal blood pressure, and echocardiographic right ventricular dysfunction. <i>Circulation</i> , 2000 , 101, 2817-22	16.7	648
315	Prognostic value of troponins in acute pulmonary embolism: a meta-analysis. <i>Circulation</i> , 2007 , 116, 427	7-363.7	506
314	A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. <i>Annals of Surgery</i> , 2006 , 243, 89-95	7.8	469
313	Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. <i>New England Journal of Medicine</i> , 2001 , 345, 165-9	59.2	467
312	Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. <i>Circulation</i> , 2004 , 110, 744-9	16.7	451
311	Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. <i>Journal of Clinical Oncology</i> , 2003 , 21, 3665-75	2.2	448

310	Aspirin for preventing the recurrence of venous thromboembolism. <i>New England Journal of Medicine</i> , 2012 , 366, 1959-67	59.2	444	
309	Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. <i>Lancet Oncology, The</i> , 2009 , 10, 943-9	21.7	443	
308	Antithrombotic therapy for venous thromboembolic disease. <i>Chest</i> , 2001 , 119, 176S-193S	5.3	439	
307	Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. <i>New England Journal of Medicine</i> , 1998 , 339, 80-5	59.2	432	
306	Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. <i>Thrombosis and Haemostasis</i> , 2007 , 98, 756-64	7	430	
305	Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. <i>New England Journal of Medicine</i> , 2012 , 366, 601-9	59.2	405	
304	Critical issues in peripheral arterial disease detection and management: a call to action. <i>Archives of Internal Medicine</i> , 2003 , 163, 884-92		398	
303	Acute pulmonary embolism. New England Journal of Medicine, 2010, 363, 266-74	59.2	337	
302	Early hemorrhagic transformation of brain infarction: rate, predictive factors, and influence on clinical outcome: results of a prospective multicenter study. <i>Stroke</i> , 2008 , 39, 2249-56	6.7	334	
301	Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. <i>New England Journal of Medicine</i> , 2020 , 382, 1599-1607	59.2	320	
300	Incidence of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism. <i>Chest</i> , 2006 , 130, 172-5	5.3	313	
299	Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. <i>Circulation</i> , 2007 , 116, 180-7	16.7	289	
298	PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2. <i>Journal of the American College of Cardiology</i> , 1992 , 20, 520-6	15.1	284	
297	A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. <i>Blood</i> , 2008 , 112, 2242-7	2.2	275	
296	Extended oral anticoagulant therapy after a first episode of pulmonary embolism. <i>Annals of Internal Medicine</i> , 2003 , 139, 19-25	8	261	
295	Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. <i>Journal of Clinical Oncology</i> , 2005 , 23, 4057-62	2.2	261	
294	Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clinical Pharmacokinetics, 2011, 50, 675-86	6.2	239	
293	Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants Odata from seven trials BM The 2011 342 d3036	5.9	234	

292	A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. <i>Internal and Emergency Medicine</i> , 2012 , 7, 291-2	3.7	231
291	Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials. <i>Stroke</i> , 2007 , 38, 423-30	6.7	223
2 90	Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. <i>Thrombosis and Haemostasis</i> , 2003 , 89, 288-296	7	221
289	Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis. <i>Chest</i> , 2015 , 147, 475-483	5.3	219
288	Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. <i>Circulation</i> , 2014 , 130, 1062-71	16.7	190
287	Low-molecular-weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: a meta-analysis. <i>Archives of Internal Medicine</i> , 2000 , 160, 2327-32		173
286	Antithrombotic therapy for venous thromboembolic disease. <i>Chest</i> , 1998 , 114, 561S-578S	5.3	170
285	Guidance for the treatment of deep vein thrombosis and pulmonary embolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2016 , 41, 32-67	5.1	167
284	Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial. <i>Annals of Internal Medicine</i> , 2009 , 150, 577-85	8	162
283	Prevention of venous thromboembolism in surgical patients. Circulation, 2004, 110, IV4-12	16.7	160
282	Early Recurrence and Cerebral Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation: Effect of Anticoagulation and Its Timing: The RAF Study. <i>Stroke</i> , 2015 , 46, 2175-82	6.7	157
281	Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. <i>European Heart Journal</i> , 2018 , 39, 4208-4218	9.5	156
280	Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. <i>Circulation</i> , 2001 , 104, 74-8	16.7	155
279	Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis. An international multicenter randomized trial. The Bolus Alteplase Pulmonary Embolism Group. <i>Chest</i> , 1994 , 106, 718-24	5.3	154
278	Multidetector computed tomography for acute pulmonary embolism: diagnosis and risk stratification in a single test. <i>European Heart Journal</i> , 2011 , 32, 1657-63	9.5	153
277	Acute pulmonary embolism: mortality prediction by the 2014 European Society of Cardiology risk stratification model. <i>European Respiratory Journal</i> , 2016 , 48, 780-6	13.6	140
276	A prospective study on cardiovascular events after acute pulmonary embolism. <i>European Heart Journal</i> , 2005 , 26, 77-83	9.5	135
275	Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism. <i>Thrombosis Research</i> , 2010 , 125, e82-6	8.2	134

(2011-2015)

274	Venous thrombosis. <i>Nature Reviews Disease Primers</i> , 2015 , 1, 15006	51.1	127
273	A randomized study on 1-week versus 4-week prophylaxis for venous thromboembolism after laparoscopic surgery for colorectal cancer. <i>Annals of Surgery</i> , 2014 , 259, 665-9	7.8	119
272	Computed tomography to assess risk of death in acute pulmonary embolism: a meta-analysis. <i>European Respiratory Journal</i> , 2014 , 43, 1678-90	13.6	114
271	Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study. <i>British Journal of Haematology</i> , 2005 , 129, 811-7	4.5	113
270	Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just one antiplatelet agent?. <i>European Heart Journal</i> , 2007 , 28, 1717-22	9.5	103
269	Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry. <i>Haematologica</i> , 2008 , 93, 273-8	6.6	99
268	The concept of ischemic penumbra in acute stroke and therapeutic opportunities. <i>European Neurology</i> , 2009 , 61, 321-30	2.1	96
267	Edoxaban: a focused review of its clinical pharmacology. <i>European Heart Journal</i> , 2014 , 35, 1844-55	9.5	90
266	Risk factors for upper limb deep vein thrombosis associated with the use of central vein catheter in cancer patients. <i>Internal and Emergency Medicine</i> , 2008 , 3, 117-22	3.7	87
265	Thrombolysis vs heparin in the treatment of pulmonary embolism: a clinical outcome-based meta-analysis. <i>Archives of Internal Medicine</i> , 2002 , 162, 2537-41		87
264	Utility of an integrated clinical, echocardiographic, and venous ultrasonographic approach for triage of patients with suspected pulmonary embolism. <i>American Journal of Cardiology</i> , 1998 , 82, 1230-	5 ³	84
263	Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. <i>BMJ, The</i> , 2019 , 366, l4363	5.9	83
262	Clinical features and short term outcomes of patients with acute pulmonary embolism. The Italian Pulmonary Embolism Registry (IPER). <i>Thrombosis Research</i> , 2012 , 130, 847-52	8.2	82
261	A Randomised, Double-Blind, Placebo-Controlled Trial of Dermatan Sulphate for Prevention of Deep Vein Thrombosis in Hip Fracture. <i>Thrombosis and Haemostasis</i> , 1992 , 67, 203-208	7	82
260	Apixaban versus Dalteparin for the Treatment of Acute Venous Thromboembolism in Patients with Cancer: The Caravaggio Study. <i>Thrombosis and Haemostasis</i> , 2018 , 118, 1668-1678	7	80
259	Endothelial dysfunction in patients with spontaneous venous thromboembolism. <i>Haematologica</i> , 2007 , 92, 812-8	6.6	8o
258	Neuroimaging in intracerebral hemorrhage. <i>Stroke</i> , 2014 , 45, 903-8	6.7	75
257	Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. <i>Journal of Translational Medicine</i> 2011 9, 179	8.5	<i>75</i>

256	Multidetector CT scan for acute pulmonary embolism: embolic burden and clinical outcome. <i>Chest</i> , 2012 , 142, 1417-1424	5.3	75
255	Systemic thrombolysis in patients with acute ischemic stroke and Internal Carotid ARtery Occlusion: the ICARO study. <i>Stroke</i> , 2012 , 43, 125-30	6.7	74
254	Association of persistent right ventricular dysfunction at hospital discharge after acute pulmonary embolism with recurrent thromboembolic events. <i>Archives of Internal Medicine</i> , 2006 , 166, 2151-6		72
253	Outcome in patients with stroke associated with internal carotid artery occlusion. <i>Cerebrovascular Diseases</i> , 2005 , 20, 108-13	3.2	68
252	What is the optimal pharmacological prophylaxis for the prevention of deep-vein thrombosis and pulmonary embolism in patients with acute ischemic stroke?. <i>Thrombosis Research</i> , 2007 , 119, 265-74	8.2	65
251	Novel approaches to the treatment of thrombosis. <i>Trends in Pharmacological Sciences</i> , 2002 , 23, 25-32	13.2	63
250	The MASTER registry on venous thromboembolism: description of the study cohort. <i>Thrombosis Research</i> , 2008 , 121, 605-10	8.2	62
249	The Comparative Effects of Recombinant Hirudin (CGP 39393) and Standard Heparin on Thrombus Growth in Rabbits. <i>Thrombosis and Haemostasis</i> , 1990 , 63, 204-207	7	61
248	Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non-Vitamin-K Oral Anticoagulants (RAF-NOACs) Study. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	60
247	Randomised, Double Blind, Multicentre, Placebo Controlled Study of Sulodexide in the Treatment of Venous Leg Ulcers. <i>Thrombosis and Haemostasis</i> , 2002 , 87, 947-952	7	60
246	Dermatan Sulphate for the Prevention of Postoperative Venous Thromboembolism in Patients with Cancer. <i>Thrombosis and Haemostasis</i> , 1999 , 82, 30-34	7	59
245	Direct oral anticoagulants versus vitamin K antagonists after recent ischemic stroke in patients with atrial fibrillation. <i>Annals of Neurology</i> , 2019 , 85, 823-834	9.4	58
244	The management of acute venous thromboembolism in clinical practice. Results from the European PREFER in VTE Registry. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 1326-1337	7	58
243	The thrombolytic and hemorrhagic effects of tissue type plasminogen activator: influence of dosage regimens in rabbits. <i>Thrombosis Research</i> , 1985 , 40, 769-77	8.2	56
242	Risk Stratification of Patients With Acute Symptomatic Pulmonary Embolism Based on Presence or Absence of Lower Extremity DVT: Systematic Review and Meta-analysis. <i>Chest</i> , 2016 , 149, 192-200	5.3	55
241	Statins and stroke prevention. <i>Cerebrovascular Diseases</i> , 2007 , 24, 170-82	3.2	55
240	Acute hyperglycemia and early hemorrhagic transformation in ischemic stroke. <i>Cerebrovascular Diseases</i> , 2009 , 28, 119-23	3.2	54
239	D-dimer for risk stratification in patients with acute pulmonary embolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2012 , 33, 48-57	5.1	53

238	Acute pulmonary embolism: external validation of an integrated risk stratification model. <i>Chest</i> , 2013 , 144, 1539-1545	5.3	53
237	Intravenous thrombolysis with rt-PA in acute ischemic stroke patients aged older than 80 years in Italy. <i>Cerebrovascular Diseases</i> , 2008 , 25, 129-35	3.2	51
236	Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: a review of the literature. <i>Thrombosis Research</i> , 2012 , 129, 392-400	8.2	49
235	Treatment of DVT: how long is enough and how do you predict recurrence. <i>Journal of Thrombosis and Thrombolysis</i> , 2008 , 25, 37-44	5.1	49
234	Treatment of Venous Thromboembolism With New Anticoagulant Agents. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 1941-55	15.1	48
233	Rationale for bolus t-PA therapy to improve efficacy and safety. <i>Chest</i> , 1990 , 97, 161S-167S	5.3	46
232	Clinically overt venous thromboembolism after urologic cancer surgery: results from the @RISTOS Study. <i>European Urology</i> , 2007 , 51, 130-5; discussion 136	10.2	44
231	Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 1128-1136	7	43
230	Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer: Results from a Global Prospective Study (CANTARISK). <i>Oncologist</i> , 2018 , 23, 247-255	5.7	42
229	Thrombophilic abnormalities and recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatment. <i>Thrombosis Research</i> , 2005 , 116, 301-6	8.2	42
228	Risk of recurrent cerebrovascular events in patients with cryptogenic stroke or transient ischemic attack and patent foramen ovale: the FORI (Foramen Ovale Registro Italiano) study. <i>Cerebrovascular Diseases</i> , 2011 , 31, 109-16	3.2	41
227	Therapy Insight: venous-catheter-related thrombosis in cancer patients. <i>Nature Clinical Practice Oncology</i> , 2006 , 3, 214-22		40
226	Effect of on-admission antiplatelet treatment on patients with cerebral hemorrhage. <i>Cerebrovascular Diseases</i> , 2007 , 24, 215-8	3.2	40
225	Venous Thromboembolism and Gancer: a Two-Way Clinical Association. <i>Thrombosis and Haemostasis</i> , 1997 , 78, 117-120	7	40
224	Major bleeding with vitamin K antagonists or direct oral anticoagulants in real-life. <i>International Journal of Cardiology</i> , 2017 , 227, 261-266	3.2	39
223	Gender differences in patients with acute ischemic stroke. Womenm Health, 2010, 6, 51-7	3	38
222	Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. <i>Thrombosis and Haemostasis</i> , 2003 , 89, 288-96	7	38
221	Thrombolysis in hemodynamically stable patients with acute pulmonary embolism: a meta-analysis. <i>Thrombosis Research</i> , 2014 , 134, 1265-71	8.2	37

220	Morbidity and mortality associated with atherosclerotic peripheral artery disease: A systematic review. <i>Atherosclerosis</i> , 2020 , 293, 94-100	3.1	37
219	Aspirin for prevention and treatment of venous thromboembolism. <i>Blood Reviews</i> , 2014 , 28, 103-8	11.1	35
218	The management of acute venous thromboembolism in clinical practice - study rationale and protocol of the European PREFER in VTE Registry. <i>Thrombosis Journal</i> , 2015 , 13, 41	5.6	35
217	Hemorrhagic Transformation in Patients With Acute Ischemic Stroke and Atrial Fibrillation: Time to Initiation of Oral Anticoagulant Therapy and Outcomes. <i>Journal of the American Heart Association</i> , 2018 , 7, e010133	6	35
216	Intravenous thrombolysis or endovascular therapy for acute ischemic stroke associated with cervical internal carotid artery occlusion: the ICARO-3 study. <i>Journal of Neurology</i> , 2015 , 262, 459-68	5.5	33
215	Admission leukocytosis in acute cerebral ischemia: influence on early outcome. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2012 , 21, 819-24	2.8	33
214	Obesity and the risk of intracerebral hemorrhage: the multicenter study on cerebral hemorrhage in Italy. <i>Stroke</i> , 2013 , 44, 1584-9	6.7	33
213	Prevention of venous thromboembolism. <i>Thrombosis Research</i> , 2000 , 97, V49-62	8.2	33
212	Post Discharge Clinically Overt Venous Thromboembolism in Orthopaedic Surgery Patients with Negative Venography -an Overview Analysis. <i>Thrombosis and Haemostasis</i> , 1996 , 76, 0887-0892	7	32
211	Causes and Risk Factors of Cerebral Ischemic Events in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention. <i>Stroke</i> , 2019 , 50, 2168-2174	6.7	31
210	Timing of anticoagulation therapy in patients with acute ischaemic stroke and atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2016 , 116, 410-6	7	31
209	Prediction of Early Recurrent Thromboembolic Event and Major Bleeding in Patients With Acute Stroke and Atrial Fibrillation by a Risk Stratification Schema: The ALESSA Score Study. <i>Stroke</i> , 2017 , 48, 726-732	6.7	28
208	Risk factors for cerebral ischemic events in patients with atrial fibrillation on warfarin for stroke prevention. <i>Atherosclerosis</i> , 2010 , 212, 564-6	3.1	28
207	Incidence of Ct scan-detected pulmonary embolism in patients with oncogene-addicted, advanced lung adenocarcinoma. <i>Thrombosis Research</i> , 2015 , 136, 924-7	8.2	27
206	Prognostic value of trans-thoracic echocardiography in patients with acute stroke and atrial fibrillation: findings from the RAF study. <i>Journal of Neurology</i> , 2016 , 263, 231-237	5.5	27
205	Prolonged antithrombin activity of low-molecular-weight heparins. Clinical implications for the treatment of thromboembolic diseases. <i>Circulation</i> , 1995 , 92, 2819-24	16.7	27
204	Acute myocardial infarction and heart failure in acute stroke patients: frequency and influence on clinical outcome. <i>Journal of Neurology</i> , 2012 , 259, 106-10	5.5	26
203	Antithrombotic medications and the etiology of intracerebral hemorrhage: MUCH-Italy. <i>Neurology</i> , 2014 , 82, 529-35	6.5	26

202	96 hours ECG monitoring for patients with ischemic cryptogenic stroke or transient ischaemic attack. <i>Internal and Emergency Medicine</i> , 2014 , 9, 65-7	3.7	25
201	Long-term death and recurrence in patients with acute venous thromboembolism: the MASTER registry. <i>Thrombosis Research</i> , 2012 , 130, 369-73	8.2	25
200	Seasonal variation in the occurrence of venous thromboembolism: data from the MASTER Registry. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2009 , 15, 309-15	3.3	25
199	Recurrent venous thromboembolism in men and women. <i>New England Journal of Medicine</i> , 2004 , 351, 2015-8; author reply 2015-8	59.2	25
198	Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD - AF Registry. <i>Journal of the American Heart Association</i> , 2019 , 8, e010510	6	24
197	The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 1940-1951	15.4	24
196	Cancer-associated ischemic stroke: A retrospective multicentre cohort study. <i>Thrombosis Research</i> , 2018 , 165, 33-37	8.2	24
195	Antithrombotic therapy for prophylaxis and treatment of venous thromboembolism in patients with cancer: review of the literature on current practice and emerging options. <i>ESMO Open</i> , 2017 , 2, e000188	6	23
194	A prospective study on survival in cancer patients with and without venous thromboembolism. <i>Internal and Emergency Medicine</i> , 2014 , 9, 559-67	3.7	23
193	Epidemiology of cerebral vein and sinus thrombosis. <i>Frontiers of Neurology and Neuroscience</i> , 2008 , 23, 16-22	1.1	23
192	Detection of Asymptomatic Deep Vein Thrombosis by Real-Time B-Mode Ultrasonography in Hip Surgery Patients. <i>Thrombosis and Haemostasis</i> , 1992 , 68, 257-260	7	23
191	Efficacy of Rivaroxaban for thromboprophylaxis after Knee Arthroscopy (ERIKA). A phase II, multicentre, double-blind, placebo-controlled randomised study. <i>Thrombosis and Haemostasis</i> , 2016 , 116, 349-55	7	22
190	Patients with cancer and atrial fibrillation treated with doacs: A prospective cohort study. <i>International Journal of Cardiology</i> , 2018 , 269, 152-157	3.2	22
189	Risk for Major Bleeding in Patients Receiving Ticagrelor Compared With Aspirin After Transient Ischemic Attack or Acute Ischemic Stroke in the SOCRATES Study (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes). <i>Circulation</i> , 2017 , 136, 907-9	16.7 1 16	22
188	Dermatan sulphate in heparin-induced thrombocytopenia. <i>Lancet, The</i> , 1994 , 344, 1295-6	40	22
187	Ticagrelor Added to Aspirin in Acute Nonsevere Ischemic Stroke or Transient Ischemic Attack of Atherosclerotic Origin. <i>Stroke</i> , 2020 , 51, 3504-3513	6.7	22
186	Serum cholesterol levels, HMG-CoA reductase inhibitors and the risk of intracerebral haemorrhage. The Multicenter Study on Cerebral Haemorrhage in Italy (MUCH-Italy). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 924-9	5.5	22
185	Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study. <i>Thrombosis and Haemostasis</i> , 2021 , 121, 616-62.	4 7	21

184	Efficacy and safety of anticoagulant agents in patients with venous thromboembolism and cancer: A network meta-analysis. <i>Thrombosis Research</i> , 2018 , 170, 175-180	8.2	21
183	Permanent discontinuation of non vitamin K oral anticoagulants in real life patients with non-valvular atrial fibrillation. <i>International Journal of Cardiology</i> , 2017 , 236, 363-369	3.2	20
182	Incidence and risk factors for venous thromboembolism after laparoscopic surgery for colorectal cancer. <i>Haematologica</i> , 2015 , 100, e35-8	6.6	20
181	Preoperative enoxaparin versus postoperative semuloparin thromboprophylaxis in major abdominal surgery: a randomized controlled trial. <i>Annals of Surgery</i> , 2014 , 259, 1073-9	7.8	20
180	Intravenous thrombolysis for acute ischemic stroke associated to extracranial internal carotid artery occlusion: the ICARO-2 study. <i>Cerebrovascular Diseases</i> , 2012 , 34, 430-5	3.2	20
179	New anticoagulants for the prevention of venous thromboembolism. <i>Drug Design, Development and Therapy</i> , 2010 , 4, 49-60	4.4	20
178	Bolus thrombolysis in venous thromboembolism. <i>Chest</i> , 1992 , 101, 172S-182S	5.3	20
177	Desmopressin-induced improvement of abnormal coagulation in chronic liver disease. <i>Lancet, The</i> , 1983 , 1, 645	40	20
176	Predictive value of admission blood glucose level on short-term mortality in acute cerebral ischemia. <i>Journal of Diabetes and Its Complications</i> , 2012 , 26, 70-6	3.2	19
175	Risk factors for venous thromboembolism in the elderly: results of the master registry. <i>Blood Coagulation and Fibrinolysis</i> , 2008 , 19, 663-7	1	19
174	The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 14-38	7	19
173	Patients aged 90 years or older with atrial fibrillation treated with oral anticoagulants: A multicentre observational study. <i>International Journal of Cardiology</i> , 2019 , 281, 56-61	3.2	18
172	Severity of acute intracerebral haemorrhage, elderly age and atrial fibrillation: independent predictors of poor outcome at three months. <i>European Journal of Internal Medicine</i> , 2013 , 24, 310-3	3.9	18
171	Risk assessment for recurrence and optimal agents for extended treatment of venous thromboembolism. <i>Hematology American Society of Hematology Education Program</i> , 2013 , 2013, 471-7	3.1	18
170	Current issues in anticoagulation. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2005 , 34 Suppl 1, 2-9		18
169	Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD-VTE patients. <i>Journal of Thrombosis and Haemostasis</i> , 2019 , 17, 1694-1706	15.4	17
168	Anticoagulation After Stroke in Patients With Atrial Fibrillation. <i>Stroke</i> , 2019 , 50, 2093-2100	6.7	17
167	Alcohol intake and the risk of intracerebral hemorrhage in the elderly: The MUCH-Italy. <i>Neurology</i> , 2018 , 91, e227-e235	6.5	17

166	Non-neurological complications of acute stroke: frequency and influence on clinical outcome. <i>Internal and Emergency Medicine</i> , 2011 , 6 Suppl 1, 119-23	3.7	17	
165	A Randomized Double-Blind Placebo-Controlled Study on Nadroparin for Prophylaxis of Thromboembolic Events in Cancer Patients Receiving Chemotherapy: The PROTECHT Study. <i>Blood</i> , 2008 , 112, 6-6	2.2	17	
164	Risk stratification and management of acute pulmonary embolism. <i>Hematology American Society of Hematology Education Program</i> , 2016 , 2016, 404-412	3.1	17	
163	Pulmonary embolism in Europe - Burden of illness in relationship to healthcare resource utilization and return to work. <i>Thrombosis Research</i> , 2018 , 170, 181-191	8.2	16	
162	New oral anticoagulants for the treatment of venous thromboembolism. <i>Best Practice and Research in Clinical Haematology</i> , 2013 , 26, 151-61	4.2	16	
161	Prevention of venous thromboembolism in immobilized neurological patients: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). <i>Thrombosis Research</i> , 2009 , 124, e26-31	8.2	16	
160	The prophylaxis of venous thrombosis in patients with cancer undergoing major abdominal surgery: emerging options. <i>Journal of Surgical Oncology</i> , 2007 , 96, 265-72	2.8	16	
159	Need for extensive diagnostic work-up for patients with lacunar stroke. <i>Journal of Neurology</i> , 2008 , 255, 637-42	5.5	16	
158	Risk factors for adverse short-term outcome in patients with pulmonary embolism. <i>Thrombosis Research</i> , 2001 , 103, V239-44	8.2	16	
157	Health-related quality of life and mortality in patients with pulmonary embolism: a prospective cohort study in seven European countries. <i>Quality of Life Research</i> , 2019 , 28, 2111-2124	3.7	15	
156	The effect of low-molecular-weight heparin in cancer patients: the mirror image of survival?. <i>Blood</i> , 2014 , 124, 155-6	2.2	15	
155	Postoperative Melagatran/Ximelagatran for the Prevention of Venous Thromboembolism following Major Elective Orthopaedic Surgery: Effects of Timing of First Dose and Risk Factors for Thromboembolism and Bleeding Complications on Efficacy and Safety. <i>Clinical Drug Investigation</i> ,	3.2	15	
154	Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. <i>European Journal of Cancer</i> , 2021 , 148, 371-381	7.5	15	
153	Risk of recurrent venous thromboembolism after acute pulmonary embolism: Role of residual pulmonary obstruction and persistent right ventricular dysfunction. A meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2019 , 17, 1217-1228	15.4	14	
152	Carotid atherosclerosis and risk for ischemic stroke in patients with atrial fibrillation on oral anticoagulant treatment. <i>Atherosclerosis</i> , 2018 , 271, 177-181	3.1	14	
151	Thromboprophylaxis with enoxaparin and direct oral anticoagulants in major orthopedic surgery and acutely ill medical patients: a meta-analysis. <i>Internal and Emergency Medicine</i> , 2017 , 12, 1291-1305	3.7	14	
150	Combined oral anticoagulants and antiplatelets: benefits and risks. <i>Internal and Emergency Medicine</i> , 2010 , 5, 281-90	3.7	14	
149	A commentary: to screen for calf DVT or not to screen? The highly variable practice among Italian centers highlights this important and still unresolved clinical option. Results from the Italian MASTER registry. Thrombosis and Haemostasis 2008, 99, 241-4	7	14	

148	Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Results from the AMPLIFY trial. <i>Thrombosis and Haemostasis</i> , 2016 , 116, 1159-1164	7	14
147	Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life. <i>European Journal of Internal Medicine</i> , 2016 , 33, 42-6	3.9	14
146	Anticoagulant treatment for acute pulmonary embolism: a pathophysiology-based clinical approach. <i>European Respiratory Journal</i> , 2015 , 45, 1142-9	13.6	13
145	Pros and cons of new oral anticoagulants in the treatment of venous thromboembolism in patients with cancer. <i>Internal and Emergency Medicine</i> , 2015 , 10, 651-6	3.7	13
144	Mortality in patients with intracerebral hemorrhage associated with antiplatelet agents, oral anticoagulants or no antithrombotic therapy. <i>European Journal of Internal Medicine</i> , 2020 , 75, 35-43	3.9	13
143	Lung ultrasound in the diagnosis of stroke-associated pneumonia. <i>Internal and Emergency Medicine</i> , 2014 , 9, 173-8	3.7	13
142	New and old anticoagulants in cancer. <i>Thrombosis Research</i> , 2012 , 129 Suppl 1, S101-5	8.2	13
141	Thrombolytic and Haemorrhagic Effects of Bolus Doses of Tissue-Type Plasminogen Activator and a Hybrid Plasminogen Activator with Prolonged Plasma Half-Life (K2tu-PA: CGP 42935). <i>Thrombosis and Haemostasis</i> , 1993 , 70, 294-300	7	13
140	Clinical Outcome of Orthopaedic Patients with Negative Lower Limb Venography at Discharge. <i>Thrombosis and Haemostasis</i> , 1995 , 74, 1042-1044	7	13
139	Right ventricle assessment in patients with pulmonary embolism at low risk for death based on clinical models: an individual patient data meta-analysis. <i>European Heart Journal</i> , 2021 , 42, 3190-3199	9.5	13
138	Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial. <i>Thrombosis and Haemostasis</i> , 2016 , 115, 809-16	7	13
137	Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism. Journal of Thrombosis and Thrombolysis, 2019 , 48, 439-453	5.1	12
136	Efficacy and safety of direct oral anticoagulants after pulmonary embolism: a meta-analysis. <i>International Journal of Cardiology</i> , 2014 , 177, 601-3	3.2	12
135	Anticoagulation in the prevention and treatment of pulmonary embolism. <i>Chest</i> , 1995 , 107, 39S-44S	5.3	12
134	Determinants of outcome in patients eligible for thrombolysis for ischemic stroke. <i>Vascular Health and Risk Management</i> , 2007 , 3, 749-54	4.4	12
133	Padua prediction score or clinical judgment for decision making on antithrombotic prophylaxis: a quasi-randomized controlled trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2016 , 42, 336-9	5.1	12
132	Acute treatment of venous thromboembolism. <i>Blood</i> , 2020 , 135, 305-316	2.2	12
131	Perspectives on antithrombotic agents: from unfractionated heparin to new antithrombotics. <i>Haematologica</i> , 2002 , 87, 757-70	6.6	12

(2005-2018)

130	Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study. <i>Thrombosis Journal</i> , 2018 , 16, 9	5.6	11
129	Diagnosis and prognosis of acute pulmonary embolism: focus on serum troponins. <i>Expert Review of Molecular Diagnostics</i> , 2008 , 8, 339-49	3.8	11
128	Prevention of venous thromboembolism after acute spinal cord injury with low-dose heparin or low-molecular-weight heparin. <i>Thrombosis and Haemostasis</i> , 2008 , 99, 978-80	7	11
127	New anticoagulants. Seminars in Thrombosis and Hemostasis, 2006, 32, 793-802	5.3	11
126	A Phase II Study of the Safety and Efficacy of a Novel Oral fXa Inhibitor (LY517717) for the Prevention of Venous Thromboembolism Following TKR or THR <i>Blood</i> , 2005 , 106, 278-278	2.2	11
125	Prediction of major bleeding in patients receiving DOACs for venous thromboembolism: A prospective cohort study. <i>International Journal of Cardiology</i> , 2020 , 301, 167-172	3.2	11
124	Updated meta-analysis on prevention of venous thromboembolism in ambulatory cancer patients. <i>Haematologica</i> , 2020 , 105, 838-848	6.6	11
123	Thrombosis and cancer: clinical relevance of a dangerous liaison. <i>Haematologica</i> , 2005 , 90, 154-6	6.6	11
122	Acute stroke symptoms: do differences exist between sexes?. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2014 , 23, 2928-2933	2.8	10
121	Thromboprophylaxis during chemotherapy in patients with advanced cancer. <i>Thrombosis Research</i> , 2010 , 125 Suppl 2, S17-20	8.2	10
120	Right ventricle dysfunction in patients with pulmonary embolism. <i>Internal and Emergency Medicine</i> , 2010 , 5, 453-5	3.7	10
119	Pharmacokinetic optimisation of the treatment of deep vein thrombosis. <i>Clinical Pharmacokinetics</i> , 1997 , 32, 145-72	6.2	10
118	Clinical benefit of early anticoagulation in cardioembolic stroke. Cerebrovascular Diseases, 2008, 25, 289)- <u>9</u> .6	10
117	Holter monitoring to detect silent atrial fibrillation in high-risk subjects: the Perugia General Practitioner Study. <i>Internal and Emergency Medicine</i> , 2015 , 10, 595-601	3.7	9
116	Direct oral anticoagulants in the secondary prevention of stroke and transient ischemic attack in patients with atrial fibrillation. <i>Internal and Emergency Medicine</i> , 2015 , 10, 555-60	3.7	9
115	Symptoms and clinical relevance: a dilemma for clinical trials on prevention of venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2013 , 109, 585-8	7	9
114	Initial treatment of venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2006 , 96, 242-50	7	9
113	Direct thrombin inhibitors for the prevention of venous thromboembolism after major orthopaedic surgery. <i>Current Pharmaceutical Design</i> , 2005 , 11, 3885-91	3.3	9

112	Clinical and economic aspects of managing venous thromboembolism in the outpatient setting. <i>Seminars in Hematology</i> , 2001 , 38, 58-66	4	9
111	Dermatan sulphate in patients with heparin-induced thrombocytopenia. <i>British Journal of Haematology</i> , 1999 , 104, 87-9	4.5	9
110	Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 461-466	7	9
109	Global thromboelastometry in patients receiving direct oral anticoagulants: the RO-DOA study. Journal of Thrombosis and Thrombolysis, 2020 , 49, 251-258	5.1	9
108	The global Edoxaban Treatment in routine cliNical prActice (ETNA) noninterventional study program: rationale and design. <i>Clinical Cardiology</i> , 2019 , 42, 1147-1154	3.3	8
107	Prevalence of risk factors for venous thromboembolism in the Italian population: results of a cross-sectional study from the Master Registry. <i>Internal and Emergency Medicine</i> , 2013 , 8, 575-80	3.7	8
106	Reversal of dabigatran-associated bleeding using idarucizumab: review of the current evidence. <i>Journal of Thrombosis and Thrombolysis</i> , 2017 , 44, 527-535	5.1	8
105	The role of heparin lead-in in the real-world management of acute venous thromboembolism: The PREFER in VTE registry. <i>Thrombosis Research</i> , 2017 , 157, 181-188	8.2	8
104	Attitudes to prescribing compression stockings for patients with acute DVT: the MASTER registry. Journal of Thrombosis and Thrombolysis, 2009 , 28, 389-93	5.1	8
103	Clinically relevant non-major bleeding with oral anticoagulants: non-major may not be trivial. <i>Blood Transfusion</i> , 2018 , 16, 387-391	3.6	8
102	Experimental Pharmacology of Hirunorm: a Novel Synthetic Peptide Thrombin Inhibitor. <i>Thrombosis and Haemostasis</i> , 1996 , 76, 384-392	7	8
101	Intrinsically Defective or Exhausted Platelets in Hairy Cell Leukemia?. <i>Thrombosis and Haemostasis</i> , 1981 , 46, 572-572	7	8
100	Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis. <i>Lancet Haematology,the</i> , 2020 , 7, e746-e755	14.6	8
99	Bedside sonography assessment of extravascular lung water increase after major pulmonary resection in non-small cell lung cancer patients. <i>Journal of Thoracic Disease</i> , 2018 , 10, 4077-4084	2.6	8
98	Thromboprophylaxis with low-molecular-weight heparins: an assessment of the methodological quality of studies. <i>Seminars in Thrombosis and Hemostasis</i> , 2015 , 41, 113-32	5.3	7
97	New strategies of VTE prevention in cancer patients. <i>Thrombosis Research</i> , 2014 , 133 Suppl 2, S128-32	8.2	7
96	Low levels of low-density lipoprotein cholesterol increase hemorrhagic transformation but not parenchimal hematoma in large artery atherothrombosisis. <i>Stroke</i> , 2009 , 40, e544; author reply e545	6.7	7
95	Clinical presentation and in-hospital death in acute pulmonary embolism: does cancer matter?. <i>Internal and Emergency Medicine</i> , 2016 , 11, 817-24	3.7	7

(2006-2021)

94	Management of Cancer-Associated Thrombosis: Unmet Needs and Future Perspectives. <i>TH Open</i> , 2021 , 5, e376-e386	2.7	7
93	Long-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism: A Systematic Review and Meta-analysis. <i>Annals of Internal Medicine</i> , 2021 , 174, 1420-1429	8	7
92	Acute pulmonary embolism: mortality prediction by the 2014 European Society of Cardiology risk stratification model. <i>European Respiratory Journal</i> , 2017 , 49,	13.6	6
91	Edoxaban in Atrial Fibrillation and Venous Thromboembolism-Ten Key Questions and Answers: A Practical Guide. <i>Advances in Therapy</i> , 2017 , 34, 620-637	4.1	6
90	The complexity of patients hospitalized in Internal Medicine wards evaluated by FADOI-COMPLIMED score(s). A hypothetical approach. <i>PLoS ONE</i> , 2018 , 13, e0195805	3.7	6
89	Gull de prlitica clilica de la ESC 2014 sobre el diagnilitico y el tratamiento de la embolia pulmonar aguda. <i>Revista Espanola De Cardiologia</i> , 2015 , 68, 64.e1-64.e45	1.5	6
88	Thromboprophylaxis during chemotherapy after advanced cancer. <i>Thrombosis Research</i> , 2007 , 120 Suppl 2, S128-32	8.2	6
87	Clinical potential of oral direct thrombin inhibitors in the prevention and treatment of venous thromboembolism. <i>Drugs</i> , 2004 , 64 Suppl 1, 47-52	12.1	6
86	Optimal dosage regimens of tissue-type plasminogen activator. <i>Seminars in Thrombosis and Hemostasis</i> , 1987 , 13, 160-2	5.3	6
85	The Additive Effect of Low Molecular Weight Heparins on Thrombin Inhibition by Dermatan Sulfate. <i>Thrombosis and Haemostasis</i> , 1993 , 70, 443-447	7	6
84	Lacunar stroke syndromes as predictors of lacunar and non-lacunar infarcts on neuroimaging: a hospital-based study. <i>Internal and Emergency Medicine</i> , 2020 , 15, 429-436	3.7	6
83	Prestroke CHADS-VASc Score and Severity of Acute Stroke in Patients with Atrial Fibrillation: Findings from RAF Study. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2017 , 26, 1363-1368	2.8	5
82	Long-term risk of recurrence after discontinuing anticoagulants for a first unprovoked venous thromboembolism: protocol for a systematic review and meta-analysis. <i>BMJ Open</i> , 2017 , 7, 16950	3	5
81	Prognostic value of respiratory index in haemodynamically stable patients with acute pulmonary embolism: The Respiratory Index model study. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020 , 9, 286-292	4.3	5
80	Safety of Anticoagulation in Patients Treated With Urgent Reperfusion for Ischemic Stroke Related to Atrial Fibrillation. <i>Stroke</i> , 2020 , 51, 2347-2354	6.7	5
79	The management of patients with venous thromboembolism in Italy: insights from the PREFER in VTE registry. <i>Internal and Emergency Medicine</i> , 2016 , 11, 1095-1102	3.7	5
78	Duration of anticoagulant treatment and recurrence of venous thromboembolism in patients with and without thrombophilic abnormalities. <i>Thrombosis and Haemostasis</i> , 2009 , 101, 596-598	7	5
77	Assessment of bleeding after concomitant administration of antiplatelet and anticoagulant agents in lower limb arthroplasty. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2006 , 35, 428-34		5

76	Comparison of quality of life measurements: EQ-5D-5L versus disease/treatment-specific measures in pulmonary embolism and deep vein thrombosis. <i>Quality of Life Research</i> , 2019 , 28, 1155-1177	3.7	5
75	Ticagrelor Added to Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack in Prevention of Disabling Stroke: A Randomized Clinical Trial. <i>JAMA Neurology</i> , 2020 ,	17.2	5
74	Concomitant Use of Direct Oral Anticoagulants and Antiepileptic Drugs: A Prospective Cohort Study in Patients with Atrial Fibrillation. <i>Clinical Drug Investigation</i> , 2021 , 41, 43-51	3.2	5
73	The impact of co-morbidity on the disease burden of VTE. <i>Journal of Thrombosis and Thrombolysis</i> , 2018 , 46, 507-515	5.1	5
72	Apixaban and Dalteparin for the Treatment of Venous Thromboembolism in Patients with Different Sites of Cancer. <i>Thrombosis and Haemostasis</i> , 2021 ,	7	5
71	The year in cardiology 2016: peripheral circulation. European Heart Journal, 2017, 38, 1028-1033	9.5	4
70	ETNA VTE Europe: A contemporary snapshot of patients treated with edoxaban in clinical practice across eight European countries. <i>European Journal of Internal Medicine</i> , 2020 , 82, 48-55	3.9	4
69	Definition of major bleeding: Prognostic classification. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 2852-2860	15.4	4
68	Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: Insights from the Caravaggio study. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 2751-2759	15.4	4
67	SMASH-U classification: a tool for aetiology-oriented management of patients with acute haemorrhagic stroke. <i>Internal and Emergency Medicine</i> , 2021 , 16, 109-114	3.7	4
66	Long-term outcome in patients with non-valvular atrial fibrillation on dabigatran: a prospective cohort study. <i>Expert Opinion on Drug Safety</i> , 2018 , 17, 1063-1069	4.1	4
65	Derivation and Validation of a Prediction Model for Venous Thromboembolism in Primary Care. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 692-701	7	3
64	Acute hematoma expansion after spontaneous intracerebral hemorrhage: risk factors and impact on long-term prognosis. <i>Neurological Sciences</i> , 2020 , 41, 2503-2509	3.5	3
63	Antithrombotic therapy for patients with an indication for oral anticoagulation undergoing percutaneous coronary intervention with stent: The case of venous thromboembolism. <i>International Journal of Cardiology</i> , 2018 , 269, 75-79	3.2	3
62	End points in studies on the prevention of deep vein thrombosis. <i>Seminars in Thrombosis and Hemostasis</i> , 2001 , 27, 41-6	5.3	3
61	Plasma thrombin neutralization assay: pharmacokinetic applications. <i>Seminars in Thrombosis and Hemostasis</i> , 1994 , 20, 266-73	5.3	3
60	Thrombolytic and antithrombotic treatment in myocardial infarction: main achievements and future perspectives. <i>International Journal of Cardiology</i> , 1995 , 49 Suppl, S77-87	3.2	3
59	Oral Anticoagulants in the Oldest Old with Recent Stroke and Atrial Fibrillation. <i>Annals of Neurology</i> , 2021 ,	9.4	3

(2020-2020)

58	Venous thromboembolism and COVID-19: Mind the gap between clinical epidemiology and patient management. <i>European Journal of Internal Medicine</i> , 2020 , 82, 18-20	3.9	3
57	A nomogram to predict unfavourable outcome in patients receiving oral anticoagulants for atrial fibrillation after stroke. <i>European Stroke Journal</i> , 2020 , 5, 384-393	5.6	3
56	Treatment of venous thromboembolism in cancer patients: The dark side of the moon. <i>Cancer Treatment Reviews</i> , 2021 , 96, 102190	14.4	3
55	Thrombolysis in elderly stroke patients in Italy (TESPI) trial and updated meta-analysis of randomized controlled trials. <i>International Journal of Stroke</i> , 2021 , 16, 43-54	6.3	3
54	Upper extremities deep vein thrombosis treated with oral direct anticoagulants: A prospective cohort study. <i>International Journal of Cardiology</i> , 2021 , 339, 158-163	3.2	3
53	Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT Study. <i>Thrombosis and Haemostasis</i> , 2021 ,	7	3
52	Acute Pulmonary Embolism after Discharge: Duration of Therapy and Follow-up Testing. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2017 , 38, 94-106	3.9	2
51	Sex-related differences in risk factors, type of treatment received and outcomes in patients with atrial fibrillation and acute stroke: Results from the RAF-study (Early Recurrence and Cerebral Bleeding in Patients with Acute Ischemic Stroke and Atrial Fibrillation). European Stroke Journal,	5.6	2
50	Rates and Determinants for the Use of Anticoagulation Treatment before Stroke in Patients with Known Atrial Fibrillation. <i>Cerebrovascular Diseases Extra</i> , 2020 , 10, 44-49	2.1	2
49	Clinical Predictors of Early Mortality in Colorectal Cancer Patients Undergoing Chemotherapy: Results From a Global Prospective Cohort Study. <i>JNCI Cancer Spectrum</i> , 2017 , 1, pkx009	4.6	2
48	Early recurrence in paroxysmal versus sustained atrial fibrillation in patients with acute ischaemic stroke. <i>European Stroke Journal</i> , 2019 , 4, 55-64	5.6	2
47	Prophylaxis of Venous Thromboembolism after Hospital Discharge in Internal Medicine: Findings from the Observational FADOI-NoTEVole Study. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 2043-2052	7	2
46	Evaluation, risk stratification and management of hypertensive patients in the perioperative period. <i>European Journal of Internal Medicine</i> , 2019 , 69, 1-7	3.9	2
45	Thromboprophylaxis in acutely ill medical patients: results of a survey among Italian physicians. <i>Thrombosis Research</i> , 2014 , 134, 572-7	8.2	2
44	Factor-VIIcoag kinetics in factor-VII-CRM+ and factor-VII-CRM-deficiencies. <i>British Journal of Haematology</i> , 1980 , 46, 307-9	4.5	2
43	Practical "1-2-3-4-Day" Rule for Starting Direct Oral Anticoagulants After Ischemic Stroke With Atrial Fibrillation: Combined Hospital-Based Cohort Study <i>Stroke</i> , 2022 , STROKEAHA121036695	6.7	2
42	Highlights from the 2019 International Aspirin Foundation Scientific Conference, Rome, 28 June 2019: benefits and risks of antithrombotic therapy for cardiovascular disease prevention. <i>Ecancermedicalscience</i> , 2020 , 14, 998	2.7	2
41	Rivaroxaban for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer. Design of the PRO-LAPS II STUDY. <i>European Journal of Internal Medicine</i> , 2020 , 72, 53-59	3.9	2

40	ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 months. <i>Thrombosis Research</i> , 2020 , 196, 297-304	8.2	2
39	Comparison of antithrombotic strategies in patients with cryptogenic stroke and patent foramen ovale: an updated meta-analysis. <i>Cardiovascular Drugs and Therapy</i> , 2021 , 35, 987-993	3.9	2
38	Risk Factors for Intracerebral Hemorrhage in Patients With Atrial Fibrillation on Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention. <i>Stroke</i> , 2021 , 52, 1450-1454	6.7	2
37	Safety of catheter ablation of atrial fibrillation in cancer survivors. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2021 , 60, 419-426	2.4	2
36	Clinical skills or high-tech MR in TIA patients: what makes the difference?. <i>Neurological Sciences</i> , 2018 , 39, 2091-2096	3.5	2
35	Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021 , 100, 102280	14.4	2
34	Data on the use of oral anticoagulants in nonagenarians with atrial fibrillation. <i>Data in Brief</i> , 2019 , 23, 103794	1.2	1
33	Management of heavy menstrual bleeding during direct oral anticoagulant therapy for recurrent venous thromboembolism: a case report. <i>Blood Coagulation and Fibrinolysis</i> , 2018 , 29, 391-394	1	1
32	Reply to Letter: "A Randomized Study on 1-Week Versus 4-Week Prophylaxis for Venous Thromboembolism After Laparoscopic Surgery for Colorectal Cancer". <i>Annals of Surgery</i> , 2016 , 263, e63	7.8	1
31	Type 2 Valvular Heart Disease Affects Decision Making for Anticoagulation in Patients with Atrial Fibrillation: The UMBRIA-Fibrillazione Atriale Prospective Study. <i>TH Open</i> , 2019 , 3, e157-e164	2.7	1
30	Reply to Letter: "A Randomized Study on 1-week Versus 4-week Prophylaxis for Venous Thromboembolism After Laparoscopic Surgery for Colorectal Cancer". <i>Annals of Surgery</i> , 2015 , 262, e12	23-8	1
29	Is there still a place for thrombolytic therapy in hemodynamically stable patients with acute pulmonary embolism? No. <i>Internal and Emergency Medicine</i> , 2015 , 10, 281-4	3.7	1
28	Unresolved issues in the prevention and treatment of venous thromboembolism. <i>Seminars in Thrombosis and Hemostasis</i> , 2002 , 28 Suppl 2, 33-40	5.3	1
27	New strategies for enhancing the speed and rate of coronary reperfusion. <i>American Journal of Cardiology</i> , 1993 , 72, 51G-58G	3	1
26	Predictors of Venous Thmromboembolism in Colorectal Cancer: Results from a Global Prospective Study. <i>Blood</i> , 2016 , 128, 1422-1422	2.2	1
25	Once Daily YM150, an Oral Direct Factor Xa Inhibitor, for Prevention of Venous Thromboembolism in Patients Undergoing Elective Primary Hip Replacement <i>Blood</i> , 2007 , 110, 309-309	2.2	1
24	Claims-based or clinical models for predicting 90-day post-pulmonary embolism outcomes. <i>Internal and Emergency Medicine</i> , 2017 , 12, 573-576	3.7	1
23	PREvention of VENous Thromboembolism in Hemorrhagic Stroke Patients - PREVENTIHS Study: A Randomized Controlled Trial and a Systematic Review and Meta-Analysis. <i>European Neurology</i> , 2020 , 83, 566-575	2.1	1

(2020-2020)

22	Timing of initiation of oral anticoagulants in patients with acute ischemic stroke and atrial fibrillation comparing posterior and anterior circulation strokes. <i>European Stroke Journal</i> , 2020 , 5, 374	I-3 § 3	1
21	Sex-specific differences in the presentation, clinical course, and quality of life of patients with acute venous thromboembolism according to baseline risk factors. Insights from the PREFER in VTE. European Journal of Internal Medicine, 2021, 88, 43-51	3.9	1
20	Long-term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 2801-2813	15.4	1
19	Recurrent venous thromboembolism and major bleeding in patients with localised, locally advanced or metastatic cancer: an analysis of the Caravaggio study <i>European Journal of Cancer</i> , 2022 , 165, 136-145	7.5	1
18	Recurrent Ischemic Stroke and Bleeding in Patients With Atrial Fibrillation Who Suffered an Acute Stroke While on Treatment With Nonvitamin K Antagonist Oral Anticoagulants: The RENO-EXTEND Study <i>Stroke</i> , 2022 , 101161STROKEAHA121038239	6.7	1
17	Treatment of venous thromboembolism in patients with cancer: What news from clinical trials?. <i>Thrombosis Research</i> , 2018 , 164 Suppl 1, S168-S171	8.2	O
16	Contemporary clinical management of acute pulmonary embolism: the COPE study <i>Internal and Emergency Medicine</i> , 2022 , 1	3.7	О
15	Risk factors and one-year mortality in patients with direct oral anticoagulant-associated gastrointestinal bleeding. <i>Thrombosis Research</i> , 2021 , 208, 138-144	8.2	O
14	The high-risk bleeding category of different scores in patients with venous thromboembolism: Systematic review and meta-analysis. <i>European Journal of Internal Medicine</i> , 2021 , 94, 45-55	3.9	0
13	Treatment of venous thromboembolism in patients with cancer: from clinical trials to real life. <i>Thrombosis Research</i> , 2020 , 191 Suppl 1, S123-S127	8.2	O
12	Diagnosis and Treatment of Deep Vein Thrombosis in the Emergency Department: Results of an Italian Nominal Group Technique Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020 , 26, 107602	962095	9720
11	Risk of death in patients with major bleedings while on treatment with oral anticoagulants. <i>International Journal of Cardiology</i> , 2017 , 235, 200	3.2	
10	Anticoagulation for atrial fibrillation in patients with active cancer: Reply to the Q etter to the Editor G from Dr. Sorigue et al. <i>International Journal of Cardiology</i> , 2019 , 280, 97	3.2	
9	Efficacia e sicurezza dei nuovi farmaci anticoagulanti orali rispetto al warfarin nella profilassi cardioembolica del paziente con fibrillazione atriale non valvolare. Pilluci che ombre. <i>Italian</i> Journal of Medicine, 2012 , 6, 153-169	0.5	
8	Thrombolysis for the Treatment of Pulmonary Embolism503-512		
7	Duration of anticoagulant treatment after venous thromboembolism. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2003 , 33, 354-7		
6	Vitamin K Antagonists and Novel Oral Anticoagulant 2007 , 175-184		
5	A survey on the views and attitudes of Italian physicians regarding the prophylaxis and treatment of venous thromboembolism. <i>Minerva Medica</i> , 2020 , 111, 370-372	2.2	

Solutions to Reduce Cardiovascular Events in Patients with Atrial Fibrillation. *Journal of Atrial Fibrillation*, **2012**, 5, 672

0.8

- Non-Anticoagulant Actions of Glycosaminoglycans 1996, 101-112
- Risk Scores for Death in Patients with Cancer-related Venous Thromboembolism: Still a Long Road
 Ahead. *Thrombosis and Haemostasis*, **2021**, 121, 700-702

7

Long-term therapy of pulmonary embolism. *Italian Heart Journal: Official Journal of the Italian Federation of Cardiology*, **2005**, 6, 824-9